Physician profile
Gregory C Castello
NPI 1417939323
$5,438.48
in general payments reported to CMS, 2019-2025
27 companies · $567 in 2025
The $567 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $803 · 2020: $838 · 2021: $729 · 2022: $906 · 2023: $807 · 2024: $789 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,162.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,345.67 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,019.63 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $806.88 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $433.51 | 2021-2024 | Ubrelvy |
| Avanos Medical | $245.75 | 2022-2025 | Genvisc 850 Sodium Hyaluronate |
| Bayer Healthcare Pharmaceuticals INC. | $232.39 | 2022-2024 | |
| Amarin Pharma, INC. | $163.39 | 2019-2020 | |
| Exact Sciences Corporation | $141.01 | 2024-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $129.18 | 2019 | |
| Bausch Health US, LLC | $122.77 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.19 | 2019-2021 | |
| Depuy Synthes Sales INC. | $86.17 | 2021-2024 | Orthovisc |
| Astellas Pharma US INC | $86.15 | 2022-2025 | Veozah |
| Orthogenrx INC. | $76.38 | 2019-2021 | |
| Bioventus LLC | $72.49 | 2022-2024 | Supartz Fx Sodium Hyaluronate |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.06 | 2021-2025 | Ofev |
| Biohaven Pharmaceutical Holding Company LTD. | $58.30 | 2022 | |
| Jazz Pharmaceuticals INC. | $55.40 | 2021 | |
| Amag Pharmaceuticals, INC. | $42.91 | 2020-2021 | |
| Eisai INC. | $40.78 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $24.10 | 2019 | |
| Corcept Therapeutics | $22.74 | 2025 | Korlym |
| Pfizer INC. | $21.43 | 2023 | |
| Idorsia Pharmaceuticals US INC | $18.46 | 2023 | Quviviq |
| Antares Pharma, INC. | $14.51 | 2019 | |
| Cashflow Solutions, LLC | $12.71 | 2023 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
| Allergan, INC. | $11.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Castello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.